Cardiovascular Systems Added to Russell 3000® Index
June 29 2009 - 1:59PM
Business Wire
Cardiovascular Systems, Inc. (CSI) (Nasdaq: CSII), a medical
device company developing and commercializing innovative
interventional treatment systems for vascular disease, has been
added to the Russell 3000� Index, which measures the performance of
the 3,000 largest U.S. companies based on total market
capitalization. The Russell Investment Group recently reconstituted
its indexes, and Russell 3000 membership went into effect June 26,
2009 and will remain in place for one year.
�Inclusion in the new Russell 3000 Index recognizes CSI�s
February 2009 debut as a publicly traded company and will enhance
our company�s visibility among investors,� said David L. Martin,
CSI president and chief executive officer. �More than 12 million
patients in the United States alone suffer from peripheral arterial
disease, and most current therapies provide poor clinical and
economic outcomes. The Diamondback 360o procedure is safe,
minimally invasive and offers dramatic advantages in recovery and
cost to patients, their families and healthcare providers. As a
result, nearly 500 hospitals have adopted our Diamondback 360o
system since the September 2007 launch.�
The Russell 3000 Index is constructed to provide a
comprehensive, unbiased and stable barometer of the broad market
and is completely reconstituted annually to ensure new and growing
equities are reflected.
About Cardiovascular Systems, Inc.
Cardiovascular Systems, Inc. is a medical device company focused
on developing and commercializing interventional treatment systems
for vascular disease. Between 8 and 12 million Americans suffer
from peripheral arterial disease (PAD), which is caused by the
accumulation of plaque in leg or foot arteries, reducing blood flow
and leading to leg pain, and eventually tissue loss and amputation.
The company�s Diamondback 360� Peripheral Arterial System is
capable of treating a broad range of plaque types both above and
below the knee, and addresses many of the limitations associated
with existing treatment alternatives. In August 2007, the U.S. FDA
granted 510(k) clearance for the use of the Diamondback 360� as a
therapy for PAD (peripheral arterial disease), and CSI commenced a
U.S. product launch in September 2007. The Diamondback 360� system
has been adopted by nearly 500 hospitals across the United States.
For more information visit the company�s Web site at
www.csi360.com.
Cardiovascular Systems (NASDAQ:CSII)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cardiovascular Systems (NASDAQ:CSII)
Historical Stock Chart
From Jul 2023 to Jul 2024